Efficacy of Dapagliflozin in the Treatment of Patients With Type 2 diabetes Hospitalized With COVID-19

Name: Efficacy of Dapagliflozin in the Treatment of Patients With Type 2 diabetes Hospitalized With COVID-19
Uploaded: 2021-07-01T18:00:00.000Z
Description: Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the efficacy of dapagliflozin in the DARE-19 trial assessing its efficacy and safety in patients with type 2 diabetes hospitalized with COVID-19.

July 1, 2021

Video

Conference|ADA Scientific Sessions - American Diabetes Association Scientific Sessions

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed the findings around the efficacy of dapagliflozin in the DARE-19 trial assessing its efficacy and safety in patients with type 2 diabetes hospitalized with COVID-19.

Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.

During the discussion, Kosiborod explained what some of the findings were around the efficacy of dapagliflozin in patients during the DARE-19 trial.